Logo
x

Search category

Subscribe Now

Severe

Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG...

  • November 11, 2021
Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG...

  • November 11, 2021
AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

  • October 8, 2021
AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

  • October 8, 2021
AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Erythematosus

AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Er...

  • August 2, 2021
AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Erythematosus

AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Er...

  • August 2, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.